| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound does not have a specific biological target; it is a chemical building block. Its primary use is as a synthetic intermediate and a targeting ligand. The boronic acid group is a key functionality for Suzuki coupling reactions, allowing for the formation of carbon-carbon bonds. It is used as a synthetic raw material for steroids, sulfonamides, antihistamines, and spirocyclic amides.
|
|---|---|
| ln Vitro |
This compound is not a biological agent and does not have in vitro activity. Its "activity" is chemical. It serves as a recognition body for polyhydroxy compounds and is an important pharmaceutical intermediate. Its utility is in the synthesis of more complex molecules, not as a therapeutic itself.
|
| ln Vivo |
This compound is not used in in vivo studies as a therapeutic agent. It is a research chemical used as a building block in the synthesis of potential drug candidates. The final drug molecule, not the boronic acid, would be tested in animals.
|
| Enzyme Assay |
Non-cellular assays are not applicable. Its utility is in organic synthesis. A typical protocol involves using this compound as a boronic acid partner in a Suzuki-Miyaura cross-coupling reaction with an aryl or vinyl halide, in the presence of a palladium catalyst and a base.
|
| Cell Assay |
This compound is not used in cell-based assays. Its applications are in synthetic chemistry. It is a solid that should be stored in a cool, dry place. It is used as a building block to synthesize compounds that may later be tested in cells.
|
| Animal Protocol |
In vivo animal experiments do not involve this compound as a test article. It is a chemical intermediate. If used to synthesize a drug candidate, that candidate would be tested in animals. The boronic acid itself is not administered.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable as this is not a drug. It is a small molecule (MW 111.89) that is a solid at room temperature. Its properties are relevant for chemical handling and storage. It has a density of 1.25 g/cm³ and a boiling point of 247.7°C.
|
| Toxicity/Toxicokinetics |
The toxicity of 3-Furanboronic acid is not extensively documented. As a boronic acid, it should be handled with standard laboratory precautions. It may be harmful if swallowed, inhaled, or absorbed through skin. It is not intended for human or veterinary use.
|
| Additional Infomation |
3-Furanboronic acid is a valuable building block in medicinal chemistry for the synthesis of pharmaceuticals and agrochemicals via Suzuki coupling reactions. It is used to introduce the furan moiety into target molecules. It is not a pharmaceutical and has no clinical trials or approved therapeutic status.
|
| Molecular Formula |
C4H5BO3
|
|---|---|
| Molecular Weight |
111.89
|
| Exact Mass |
112.033
|
| CAS # |
55552-70-0
|
| PubChem CID |
2734358
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
247.7±32.0 °C at 760 mmHg
|
| Melting Point |
139-144 °C (dec.)(lit.)
|
| Flash Point |
103.6±25.1 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.490
|
| LogP |
0.75
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
8
|
| Complexity |
75.7
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
B(C1=COC=C1)(O)O
|
| InChi Key |
CYEFKCRAAGLNHW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H5BO3/c6-5(7)4-1-2-8-3-4/h1-3,6-7H
|
| Chemical Name |
furan-3-ylboronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (1117.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (18.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (18.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (18.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.9373 mL | 44.6867 mL | 89.3735 mL | |
| 5 mM | 1.7875 mL | 8.9373 mL | 17.8747 mL | |
| 10 mM | 0.8937 mL | 4.4687 mL | 8.9373 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
